OncoMatch/Bladder Cancer (Urothelial)/HER2 (ERBB2)
Bladder Cancer (Urothelial)HER2 (ERBB2) Clinical Trials
HER2 overexpression or amplification occurs in approximately 10–15% of advanced urothelial carcinoma and has emerged as a targetable alteration following T-DXd activity in solid tumors broadly. Disitamab vedotin, a HER2-directed ADC, received FDA Breakthrough Designation in urothelial cancer. Trials investigate T-DXd, disitamab vedotin alone and in combination with pembrolizumab, and bispecific HER2 antibodies in HER2-altered urothelial carcinoma.
Top recruiting HER2 (ERBB2) Bladder Cancer (Urothelial) trials
Ranked by phase and US site count. See all 14 trials matched to your profile →
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
RemeGen Co., Ltd.
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Cancer Research UK
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen, a wholly owned subsidiary of Pfizer
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
Sun Yat-sen University
Browse other molecular targets with active Bladder Cancer (Urothelial) trials.